Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers
NCT05103241Phase 1Completed
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suraxavir marboxil in influenza, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoints: Distribution of GP681 in the whole blood and plasma up to 336 hours, Quantitive analysis of whole radioactivity of excrement up to 432 hours and 3 more. Started Oct 2021; status: completed.
02
Drugs
suraxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05103241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103241.